文献速递膀胱癌与上尿路尿路上皮癌

全基因组突变分析用于尿路上皮癌患者肿瘤知情循环肿瘤DNA检测

Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.
PubMed 文献 · Eur Urol · 2024-05-29

本研究采用肿瘤知情全基因组测序(WGS)方法,对112例接受新辅助化疗后根治性膀胱切除术的局限性肌层浸润性膀胱癌患者的916份纵向血浆样本进行循环肿瘤DNA(ctDNA)检测。WGS-based ctDNA检测可预测患者结局,中位领先影像学131天,术后检测复发灵敏度91%、特异度92%。

要点

  • WGS-based ctDNA检测可预测膀胱癌患者结局,中位领先影像学131天。
  • 根治性膀胱切除术后WGS-based ctDNA评估复发灵敏度91%、特异度92%。
  • 高ctDNA水平治疗后血浆可揭示铂类治疗相关突变特征和拷贝数变异。

核心结论

  • 结果支持使用WGS进行超灵敏ctDNA检测,并提示基于血浆追踪肿瘤演化的可能性。
  • WGS-based ctDNA检测因所需血浆量低且WGS易于执行、无需个性化检测设计,是临床应用的 promising 选择。

研究设计与样本

  • 采用肿瘤知情WGS方法进行基于ctDNA的微小残留病(MRD)检测和疗效评估。
  • 分析112例接受新辅助化疗后根治性膀胱切除术的局限性肌层浸润性膀胱癌患者的916份纵向收集血浆样本。
  • 评估无复发生存(主要终点)、总生存及新辅助化疗期间ctDNA动态。

主要发现

  • WGS-based ctDNA检测可预测患者结局,中位领先影像学131天。
  • 根治性膀胱切除术后WGS-based ctDNA评估识别复发灵敏度91%、特异度92%。
  • 高ctDNA水平治疗后血浆基因组特征揭示获得性铂类治疗相关突变特征和原发肿瘤中不存在的拷贝数变异。

局限性

  • 测序深度是研究肿瘤演化的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Circulating tumor DNA (ctDNA) can be used for sensitive detection of minimal residual disease (MRD). However, the probability of detecting ctDNA in settings of low tumor burden is limited by the number of mutations analyzed and the plasma volume available. We used a whole-genome sequencing (WGS) approach for ctDNA detection in patients with urothelial carcinoma. METHODS: We used a tumor-informed WGS approach for ctDNA-based detection of MRD and evaluation of treatment responses. We analyzed 916 longitudinally collected plasma samples from 112 patients with localized muscle-invasive bladder cancer who received neoadjuvant chemotherapy (NAC) before radical cystectomy. Recurrence-free survival (primary endpoint), overall survival, and ctDNA dynamics during NAC were assessed. KEY FINDINGS AND LIMITATIONS: We found that WGS-based ctDNA detection is prognostic for patient outcomes with a median lead time of 131 d over radiographic imaging. WGS-based ctDNA assessment after radical cystectomy identified recurrence with sensitivity of 91% and specificity of 92%. In addition, genomic characterization of post-treatment plasma samples with a high ctDNA level revealed acquisition of platinum therapy-associated mutational signatures and copy number variations not present in the primary tumors. The sequencing depth is a limitation for studying tumor evolution. CONCLUSIONS AND CLINICAL IMPLICATIONS: Our results support the use of WGS for ultrasensitive ctDNA detection and highlight the possibility of plasma-based tracking of tumor evolution. WGS-based ctDNA detection represents a promising option for clinical use owing to the low volume of plasma needed and the ease of performing WGS, eliminating the need for personalized assay design.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Nordentoft I, Lindskrog SV, Birkenkamp-Demtröder K, et al. Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma. Eur Urol. 2024. PMID: 38811314. doi:10.1016/j.eururo.2024.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。